苑东生物: 苑东生物：关于自愿披露奥沙西泮片获得药品注册证书的公告

Group 1 - The company has received the drug registration certificate for Oxazepam Tablets from the National Medical Products Administration, indicating compliance with drug registration requirements [1][2] - Oxazepam Tablets are classified as a Class 3 chemical drug with a specification of 15mg and a shelf life of 18 months [1][2] - The drug is primarily used for short-term relief of anxiety, tension, and agitation, and can also assist in treating anxiety with depression and acute alcohol withdrawal symptoms [2] Group 2 - The product was originally developed by Wyeth and later acquired by Pfizer, with the first launch in Sweden in 1966 under the brand name Sobril [2] - In 2024, the sales amount for Oxazepam Tablets in key public hospitals in China exceeded 500 million yuan, with the product's sales amounting to approximately 10.044 million yuan, reflecting a year-on-year growth of 9.58% [2] - The company has signed a cooperation agreement with Jiangsu Enhua and Xin Medical Marketing Co., Ltd., where the company will be responsible for production and supply, while Jiangsu Enhua will handle exclusive commercialization in mainland China [3]